VivoSeq
Other

Duodenal Ulcer

33

Pipeline Programs↗

1

Active Trials↗

18

Companies Involved↗

Duodenal Ulcer is a moderately active landscape with 33 programs across 18 companies. The most active players are Takeda, Shandong Luoxin Pharmaceutical Group Stock Co., Ltd., Dexcel Pharma Technologies Ltd.. 14 therapies are approved with 13 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

53/100

Pipeline Velocity

0/100

Mech. Concentration

33/100

Completion Rate

97/100

Attrition Rate

3/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Takeda logo

Takeda

4 programs

Phase 3S

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.

3 programs

Phase 3D

Dexcel Pharma Technologies Ltd.

2 programs

Phase 3L

Livzon Pharmaceutical Group Inc.

1 program

Phase 3S

Sihuan Pharmaceutical Holdings Group Ltd.

1 program

Phase 3Akero Therapeutics logo

Akero Therapeutics

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Trial Status

31

clinical trials

Completed28 · 90%
Recruiting1 · 3%
Unknown status1 · 3%
Terminated1 · 3%

Clinical Trials

Trial Activity

31 trials

Prevention of Recurrent Ulcer Bleeding in Patients With Idiopathic Gastroduodenal Ulcer
Recruiting·—·Phase 4·NCT03675672·154 enrolled
Drug Use Surveillance of Vonoprazan for "Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis"
Completed·Takeda logoTakeda·N/A·NCT03214952·3,183 enrolled
Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)
Completed·Takeda logoTakeda·Phase 3·NCT01452750·642 enrolled
Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients (Phase 2)
Completed·LLivzon Pharmaceutical Group Inc.·Phase 2·NCT00953381·235 enrolled
Special Drug Use Surveillance of Vonoprazan for "Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs: Long-term Use"
Completed·Takeda logoTakeda·N/A·NCT03214198·1,304 enrolled
Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients
Completed·LLivzon Pharmaceutical Group Inc.·Phase 2/3·NCT02847455·408 enrolled
A Study of Pariet to Prevent Gastric and Duodenal Ulcer Associated With Low-aspirin in Korean Participants With a History of Gastric and Duodenal Ulcer
Completed·Eisai logoEisai·N/A·NCT05208268·676 enrolled
Long-term Extension Study of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)
Completed·Takeda logoTakeda·Phase 3·NCT01456260·406 enrolled
A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Low-Dose Aspirin Therapy
Completed·Takeda logoTakeda·Phase 3·NCT01568398·27 enrolled
A Study of Esomeplazole (D961H) in Japanese Paediatric Patients With Reflux Esophagitis, Gastric Ulcer or Duodenal Ulcer
Completed·AstraZeneca logoAstraZeneca·Phase 3·NCT03553563·50 enrolled
Efficacy and Safety of Lansoprazole on Gastric and Duodenal Ulcers in Patients Taking Nonsteroidal Anti-Inflammatory Drugs
Completed·Takeda logoTakeda·Phase 3·NCT00787254·366 enrolled
Celebrex Low Dose ASA Study Examining the Incidence of Gastroduodenal Ulcers in a Healthy Population
Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 4·NCT00137033·605 enrolled
Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Low-dose Aspirin
Completed·Takeda logoTakeda·Phase 3·NCT01452763·621 enrolled
Long-term Use of Takepron on the Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs
Completed·Takeda logoTakeda·N/A·NCT02099708·3,502 enrolled
Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)
Completed·Eisai logoEisai·Phase 2/3·NCT01397448·472 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)